Telmisartan: A review of its use in hypertension

Drugs

Volumn 61, Issue 10, 2001, Pages 1501-1529

  Sharpe, M ^a   Jarvis, B ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TELMISARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; HUMAN; HYPERTENSION; REVIEW;

EID: 0034874986     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161100-00009     Document Type: Review

References (89)

1. Blockade of the renin-angiotensin system
2. Molecular biology of angiotensin II biosynthesis and receptors
3. Pharmacology of angiotensin II receptor antagonists: Comparison with renin inhibitors and angiotensin-converting enzyme inhibitors
4. Angiotensin II receptor antagonists
5. Angiotensin II-receptor blockers: Clinical relevance and therapeutic role
6. Telmisartan
7. A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist
8. Characterization of the pharmacodynamic/PK profile of BIBR 277-1-O-acylglucuronide, the metabolite of telmisartan
9. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
10. Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat
11. Angiotensin II receptors in the rat lung are of the AII-1 subtype
12. 1-selective angiotensin II receptor antagonist
13. Effects of ATI receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain
14. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats
15. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats
16. The effects of B1BR277, an angiotensin II type I (AT1) receptor antagonist in conscious monkeys
17. Angiotensin II receptor blockade in TGR(mREN2)27: Effects of renin-angiotensin system gene expression and cardiovascular functions
18. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade
19. Effects of telmisartan on renal excretory function in conscious dogs
20. Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium
21. Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs
22. The inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge
23. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
24. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension
25. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine
26. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
27. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring
28. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension
29. Improved LV function, systemic vascular and brachial artery parameters in hypertension: The Venezuelan telmisartan study
30. Dose response and safety of telmisartan in patients with mild to moderate hypertension
31. Acute natriuretic effect of telmisartan in hypertensive patients
32. Long-term effect of telmisartan on sodium excretion in hypertensive patients
33. Telmisartan reverses the potassium loss associated with high doses of hydrochlorothiazide
34. Effects of telmisartan on arterial compliance and endothelial function in type 2 diabetes patients with essential hypertension
35. Regression of left ventricular hypertrophy on serial echocardiography in patients treated with telmisartan
36. ARCTIC: Assessment of haemodynamic response in patients with congestive heart failure to telmisartan: A multicentre dose-ranging study in Canada
37. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure
38. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
39. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: Comparison with healthy volunteers
40. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
41. Micardis (telmisartan) tablets 40mg and 80mg prescribing information Boehringer
42. 14C]telmisartan in healthy volunteers
43. Disposition and chemical stability of telmisartan I-O-acylglucuronide
44. Structure elucidation of the main metabolite of telmisartan
45. In vitro glucuronidation of telmisartan, a novel angiotensin II receptor antagonist
46. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
47. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
48. Pharmacokinetic evidence of a lack of interaction between telmisartan and simvastatin
49. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
50. Influence of repeated oral doses of telmisartan on the clinical pharmacology of glibenclamide in healthy subjects
51. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers
52. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects
53. 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension
54. The sixth report of the Joint National Committee on prevention detection, evaluation, and treatment of high blood pressure
55. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
56. British Hypertension Society guidelines for hypertension management 1999: Summary
57. Comparison of telmisartan monotheraphy with losartan + hydrochlorothiazide in mild-to-moderate hypertension
58. Superior antihypertensive efficacy of telmisartan, a new AT1 antagonist compared to atenolol at relative low fixed doses
59. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist
60. The efficacy and safety of telmisartan compared to atenolol and placebo in patients with hypertension
61. Safety and efficacy of telmisartan versus enalapril in moderate renal failure patients with mild-to-moderate hypertension
62. Once-daily telmisartan compared with enalapril in the treatment of hypertension
63. Angiotensin II receptor antagonist micardis in isolated systolic hypertension (ARAMIS) study: Efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide or placebo
64. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study
65. Comparison of telmisartan with lisinopril in patients with mild-to- moderate hypertension
66. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension
67. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials
68. Safety and efficacy of long-term exposure to monotherapy or combination therapy with telmisartan
69. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy
70. Comparison of a fixed-dose combination of telmisartan 40 mg plus hydrochlorothiazide 12.5 mg with telmisartan 40 mg in the control of mild-to-moderate hypertension
71. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
72. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker - Telmisartan
73. Long-term, openlabel follow-up study of telmisartan monotherapy and combination therapy
74. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications
75. ACE inhibitor-induced cough and bronchospasm: Incidence, mechanisms and management
76. Cough associated with angiotensin converting enzyme inhibition
77. Micardis summary of product characteristics
78. Drug therapy: Patient compliance
79. Intrinsically long-acting agents compared with long-acting chronoformulations
80. Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II
81. Diuretics vs alpha-blockers for treatment of hypertension: Lessons from ALLHAT
82. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
83. ONTARGET fact sheet: Ongoing telmisartan alone and in combination with ramipril global end-point trial
84. TRANSCEND fact sheet: The ACE-I intolerant study telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease
85. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists
86. Newly emerging pharmacologic differences in angiotensin II receptor blockers